Publication
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Mahmoud R Gaballa, Kelley Julian, Aimaz Afrough, Doris K Hansen, Utkarsh Goel, Andre De Menezes Silva Corraes, Danai Dima, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Lindsay Fogel, Shahzad Raza, Rahul Banerjee, Saurabh S Zanwar, Oren Pasvolsky, Aishwarya Sannareddy, Azra Borogovac, James Davis, Kimberly Green, Noa Biran, Eli Zolotov, Megan Herr, Leyla Shune, Evguenia Ouchveridze, Shaun DeJarnette, Shebli Atrash, Christopher Ferreri, Tiffany Richards, Muhammad Bilal Abid, Susan Bal, Hossam M Ali, Jing Christine Ye, Shambavi Richard, Gurbakhash Kaur, Kenneth Shain, Omar Castaneda-Puglianini, Ken Harada, Gabriel De Avila, Adriana Rossi, Hamza Hassan, Larry D Anderson, Peter M Voorhees, Jack Khouri, Surbhi Sidana, Andrew J Portuguese, Murali Janakiram, Hans C Lee, Yi Lin, Ariel Grajales-Cruz, Krina K Patel, Douglas W Sborov
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell-redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as active…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available